Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 157 Carcinoma, Intraductal, Noninfiltrating 16 Breast Carcinoma In Situ 12 Neoplasm Metastasis 9 Ovarian Neoplasms 7 Breast Neoplasms, Male 7 Neoplasms 4 Prostatic Neoplasms 3 Inflammatory Breast Neoplasms 3 Glioblastoma 3 Breast Cancer Female 3 Urinary Bladder Neoplasms 2 Recurrence 2 Pancreatic Neoplasms 2 Obesity 2 Infertility 2 Hot Flashes 2 Fibroadenoma 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 ER+ Breast Cancer 2 Brain Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Sleep Wake Disorders 1 Sexuality 1 Risk Reduction Behavior 1 Rhabdoid Tumor 1 Pyloric Stenosis, Hypertrophic 1 Primary Breast Cancer 1

Interventions

lutetium Lu 177 dotatate 29 Everolimus 19 Temozolomide 11 gallium Ga 68 dotatate 10 Nivolumab 10 Magnetic Resonance Spectroscopy 10 Capecitabine 9 pembrolizumab 8 lanreotide 8 Positron Emission Tomography Computed Tomography 8 cabozantinib 7 3-Iodobenzylguanidine 7 177Lu-octreotide, DOTA(0)-Tyr(3)- 7 Somatostatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 telotristat ethyl 5 lenvatinib 5 Octreotide 5 Lutetium-177 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 Carboplatin 5 avelumab 4 Positron-Emission Tomography 4 Ipilimumab 4 Bevacizumab 4 surufatinib 3 pasireotide 3 fluorodopa F 18 3 copper dotatate CU-64 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neuroendocrine Tumors × Tamoxifen × Clear all

NCT03870399 2024-05-06

HORMONET

AC Camargo Cancer Center

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡